
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a genomic diagnostics company that is a leader in the growing market for next-generation diagnostic tests. With an expanding portfolio of advanced diagnostic tests, Veracyte is well positioned for sustained revenue growth. The recent acquisition of C2i Genomics and its minimal residual disease test for muscle-invasive bladder cancer further strengthens their position in the market. Additionally, the company's plans to launch kitted versions of their tests and expand internationally are expected to drive growth. With strong double digit growth and a unique competitive advantage in leveraging their broad urology sales channel, Veracyte has a positive outlook from a financial analyst's perspective.
Bears say
Veracyte is currently facing strong headwinds in revenue growth, with its most recent quarter only seeing an 18.5% increase in revenue, below both its own preannouncement and analyst consensus. Its recent entrance into the MRD market with the TrueMRD platform may be overshadowed by competition from other companies with similar offerings, and its projected opportunity in bladder cancer is relatively small at $200M. With a negative outlook for revenue and earnings growth, it may be difficult for Veracyte to meet its ambitious revenue and margin targets, resulting in a bear case valuation of ~$24 per share.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares